- Home
- MSTR vs MRNA Comparison
MSTR vs MRNA Comparison
Compare MSTR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSTR | MRNA |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5B | 26.7B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MSTR | MRNA |
|---|---|---|
| Price | $93.62 | $62.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | ★ $343.77 | $34.27 |
| AVG Volume (30 Days) | ★ 22.9M | 9.0M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | N/A | ★ N/A |
| Revenue | $463,456,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $5.22 | $9.36 |
| Revenue Next Year | $2.41 | $15.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $81.81 | $22.28 |
| 52 Week High | $437.00 | $85.60 |
Technical Indicators
Market Signals| Indicator | MSTR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 46.96 |
| Support Level | $81.81 | $45.69 |
| Resistance Level | $104.78 | $85.60 |
| Average True Range (ATR) | 6.20 | 4.81 |
| MACD | 2.05 | -1.84 |
| Stochastic Oscillator | 47.19 | 5.83 |
Price Performance
Historical ComparisonAbout MSTR MicroStrategy Incorporated
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software. It has one reportable operating segment: the Software Business, which is engaged in the design, development, marketing, and sales of the company's enterprise analytics software platform through cloud subscriptions and licensing arrangements and related services (i.e., product support, consulting, and education). Geographically, the company operates in EMEA, U.S. and Other Regions, of which maximum revenue is derived from U.S..
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.